| 1 |
Review A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder. 2008
DiazGranados N, Zarate CA. · Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, 10 Center Drive, CRC, Unit 7 Southeast, Room 7-3445, Bethesda, MD 20892, USA. · Curr Psychiatry Rep. · Pubmed #18980735 No free full text.
Abstract: In this article, we review preclinical studies investigating the role of protein kinase C (PKC) as it pertains to mania and effective antimanic agents. We then discuss clinical studies conducted with tamoxifen, a relatively selective PKC inhibitor, in acute bipolar mania. We conclude that PKC is an important target-arguably the first mechanistically distinct drug target for bipolar disorder. PKC holds considerable promise as a novel target for developing a new line of treatments for bipolar disorder.
|